Cyberounds Logo
August 11, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Treatment of Idiopathic Inflammatory Myopathy
Siamak Moghadam-Kia, M.D., Rohit Aggarwal, M.D. and Chester V. Oddis, M.D.

Dr. Moghadam-Kia is Assistant Professor, Dr. Aggarwal is Associate Professor and Dr. Oddis is Professor, Myositis Center and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Within the past 12 months, Dr. Aggarwal has been a consultant to Bristol-Mers Squibb, Mallinckrodt and Octapharma, and done contracted research for Bristol-Mers Squibb, Genentech, Mallinckrodt and Pfizer; Drs. Moghadam-Kia and Oddis have no conflicts of interest relevant to this activity.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.



Release Date: 12/04/2017
Termination Date: 12/04/2020
Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Discuss the role of systemic glucocorticoid therapy which is considered the mainstay of initial treatment of idiopathic inflammatory myopathies;
  • Describe the role of methotrexate or azathioprine, other immunosuppressive, immunomodulatory agents or biologic drugs that can be sequentially used alone or in various combinations in the management of polymyositis and dermatomyositis;
  • List the mechanism of action and common side effects of immunosuppressive or immunomodulatory therapies used in myositis treatment.

 
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity